Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration.

ABSTRACT: Oncogenic Ras mutants, frequently detected in human cancers, are high-priority anticancer drug targets. However, direct inhibition of oncogenic Ras mutants with small molecules has been extremely challenging. Here we report the development of a human IgG1 format antibody, RT11, which internalizes into the cytosol of living cells and selectively binds to the activated GTP-bound form of various oncogenic Ras mutants to block the interactions with effector proteins, thereby suppressing downstream signalling and exerting anti-proliferative effects in a variety of tumour cells harbouring oncogenic Ras mutants. When systemically administered, an RT11 variant with an additional tumour-associated integrin binding moiety for tumour tissue targeting significantly inhibits the in vivo growth of oncog

SUBMITTER: Shin SM 

PROVIDER: S-EPMC5436137 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature